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analysis clearly demonstrated an independently favorable role of "a usage of ACEIs (dose over the least officially recommended one)" against inception of RRT among antihypertensive agents (Table 1) . Thus, we could confirm the conclusion [1] in a local area of Japan on a micro level, as well.
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Stopping progression in familial juvenile hyperuricemic nephropathy with benzbromarone?
To the Editor: In a recent issue of Kidney International, a landmark paper on familial juvenile hyperuricemic nephropathy (FJHN) was published. Bleyer et al [1] describe a large family with the disease, which is caused by a uromodulin gene mutation. Chronic and progressive renal failure was the most prominent clinical feature. Despite treatment with allopurinol, loss of creatinine clearance (CrCl) exceeded 3 mL/min/year. Hyperuricemia in FJHN is caused by reduced fractional excretion of uric acid (FEUA). Whereas allopurinol does not affect FEUA, benzbromarone normalizes it in FJHN [2] . We treated two FJHN patients with a combination of allopurinol adjusted to renal function and benzbromarone
